Affymetrix Inc. (AFFX) CytoScan Dx Assay Receives FDA Marketing Approval

17-01-2014 StreetInsider.comComments (0)

AffymetrixBiotechnologyHealth Medical PharmaMicroarraysScienceSocial IssuesSocial Issues

Today the U.S. Food and Drug Administration authorized for marketing the Affymetrix CytoScan Dx Assay, which can detect chromosomal variations that may be responsible for a child's developmental delay or intellectual disability. Based on a blood sample ...

Read more on StreetInsider.com

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top